Our state-of-the art amenities facilitate our world-class research
Our cutting-edge drug and vaccine discovery and development resources are also available to external research groups and industry.
Explore our facilities and resources below, and if you’d like more information on any of our services, please get in touch.
A multi-million dollar investment by Griffith University allowed the establishment of a new glycomics and glycoproteomics focussed Advanced Mass Spectrometry Laboratory, embedded at the Institute for Glycomics.
As part of the Australian Centre for Cancer Glycomics (A2CG) a major focus of this Mass Spectrometry laboratory is to push the boundaries in biomedical research and working towards the discovery of new cancer diagnostics, drugs and vaccines, which will have global impact. This purpose build laboratory currently hosts three state-of-the-art high-end mass spectrometers catering for different challenges in cancer and disease glycomics.
We are using these modern technologies to understand and translate the glycome changes occurring in cancer to identify new therapeutic targets, develop novel diagnostics for precision medicine and gain a better general understanding of cancer biology.
To achieve these aims, we are using an
- Orbitrap™ Fusion™ mass spectrometer that is coupled to a nano-liquid chromatography system, enabling us to perform multi-dimensional separation, detection and fragmentation of biomolecules.
- rapifleX™ tissue imager to visualise and identify diagnostic markers in tissue sections and understand their distribution in cancer tissues
- amaZon speed ion trap mass spectrometer coupled to a nano-liquid chromatography system providing us with the opportunity to perform clinical glycomics with the highest sensitivity and selectivity.
We are also offering one-stop services and solutions for industrial glycomics and glycoproteomics challenges and questions, with the team having over 60 combined years of experience in analytical glycobiology, glycomics and glycoproteomics.
Recently established within the Institute for Glycomics, the Zymebank facility provides enzymes that support both internal and external research projects. By cloning into various mammalian or bacterial expression vectors, Zymebank is able to produce enzymes essential for glycan synthesis in high quality and purity. Activity assays have been developed to allow for in-depth characterisation of enzyme functions which guides enzyme use in downstream applications such as chemo-enzymatic synthesis. Currently, a range of human and bacterial sialyltransferases and fucosyltransferases have been expressed and characterised. Enzymes for sugar-nucleotide biosynthesis and nucleotide triphosphate regeneration are also available. We currently have nearly 30 enzymes in stock, and this number is growing rapidly. Zymebank also provides technical support in molecular cloning, expression, purification, and assay development.
- ready to use enzymes
- expression plasmids (in-house cloned)
- molecular cloning
- protein expression and purification
- assay development
In vivo models
We have in-house access to a range of in vivo models and a substantial, fully staffed facility, including PC2 and PC3 suites. We also have animal models for autoimmune inflammatory diseases.
Clinical samples and cell lines
We have a growing number of clinical samples and novel cell-lines relevant to infectious diseases and cancer research.